Company news
Invex Therapeutics Ltd. (ASX:IXC) news
Invex Therapeutics Ltd. news releases on 6ix. Latest, Feb 12, 2026: Appendix 4D and Half Year Report
Press releases & updates
Appendix 4D and Half Year Report
February 12, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 22, 2026
Reinstatement to Quotation
November 9, 2025
Board and Officer Appointments and Company Address Change
November 9, 2025
Suspension from Official Quotation
November 7, 2025
Pause in Trading
November 7, 2025
Response to ASX Price and Volume Query
September 30, 2025
Corporate Update
September 30, 2025
Suspension from Quotation
September 25, 2025
Trading Halt
September 23, 2025
Appendix 4E and Annual Report to shareholders
August 10, 2025
Invex Receives $0.22m R&D Tax Rebate from UK Government
January 19, 2025
Improved Neuronal Cell Survival in 3D Model of Alzheimer's
December 15, 2024
Quarterly Activities Report and Appendix 4C
October 7, 2024
Invex receives R&D Tax Rebate
June 21, 2024
ATO Class Ruling Return of Capital
March 20, 2024
Appendix 4D and Half year report
February 15, 2024
Invex and Peptron Mutually Terminate Manufacturing Agreement
December 21, 2023
Invex Granted European Patent for Exenatide in Hydrocephalus
November 21, 2023
Proposed Capital Return to Shareholders of $14.0 Million
November 1, 2023
Invex issued US patent for Traumatic Brain Injury
August 23, 2023
Invex to close IIH Evolve Phase III Clinical Trial
August 20, 2023
Phase III Clinical Trial Update and New IIH Market Analysis
June 27, 2023
Invex Granted European Orphan Drug Designation for TBI
June 22, 2023
Invex Receives Regulatory Approval for IIH EVOLVE in France
April 20, 2023
Israel Ministry of Health Approval for IIH EVOLVE
April 19, 2023
German Approval for IIH EVOLVE Phase 3 Clinical Trial
March 19, 2023
Half Year Accounts
February 16, 2023
First US Clinical Site Activated in IIH EVOLVE Phase III
January 18, 2023
Invex Receives Approval for Paediatric Plan from the EMA
December 13, 2022
MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ
November 24, 2022
First Patient Randomised in IIH EVOLVE Phase III Trial
November 20, 2022
Invex Receives $0.46 Million R&D Tax Rebate
October 31, 2022
First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
October 23, 2022
First Australian Site Activated in IIH EVOLVE Phase 3
October 23, 2022
Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
September 29, 2022
4E and Annual Report to shareholders
August 18, 2022
Invex receives IND approval
August 18, 2022
Invex Therapeutics : Quarterly Activities/Appendix 4C Cash Flow Report
July 5, 2022
HREC and TGA Approval to Commence Phase 3 in Australia
July 3, 2022
Invex Receives UK Approval to Commence Phase III Trial
June 28, 2022
Half Yearly Report and Accounts
February 22, 2022
New Executive Director and Chairman Agreements
January 30, 2022
Appointment IIH EVOLVE Phase III Trial Steering Group Chair
December 16, 2021
Invex Therapeutics : Chairman's Address to Shareholders at AGM
November 25, 2021
Global Phase 3 Trial of Presendin to Launch in Q4 2021
November 3, 2021
Notice of Investor Call and Presentation
September 27, 2021
Exclusive Collaboration and Manufacturing Agreement
September 27, 2021
Appendix 4E and Annual Report
August 26, 2021
Invex Granted Key European Patent for Exenatide
August 16, 2021